European Association of Urology Annual Congress (EAU22)
Amsterdam, the Netherlands 01 July 2022 - 04 July 2022
Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa
Use of the oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix led to faster and greater sustained profound testosterone suppression than leuprolide in men with advanced prostate cancer, according to results of the phase III HERO study presented at EAU 2022.
Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa
25 Aug 2022
Is 5-year interval sufficient for prostate cancer screening in older men?
Diagnosis, progression, or death due to prostate cancer occur at approximately a decade to 15 years following an initial assessment of prostate-specific antigen (PSA) levels in older men, according to a study presented at EAU 2022.
Is 5-year interval sufficient for prostate cancer screening in older men?
18 Aug 2022
Avelumab benefit may extend to cisplatin-unfit bladder cancer patients
The anti-PD-L1 antibody avelumab demonstrated clinical activity as first-line treatment for patients with metastatic or locally advanced urothelial carcinoma who were PD-L1-positive and ineligible for cisplatin, according to findings from the ARIES trial presented at EAU 2022.
Avelumab benefit may extend to cisplatin-unfit bladder cancer patients
08 Aug 2022
Abiraterone-olaparib confers clinical benefit for mCRPC patients
The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.
Abiraterone-olaparib confers clinical benefit for mCRPC patients
04 Aug 2022
Which drugs raise risk of urinary tract infections?
Some medications may directly cause the occurrence of urinary tract infections (UTIs), and a recent study presented at the 37th Annual European Association of Urology Congress (EAU 2022) has identified six drugs that appear to contribute to “significant reporting levels” for infections.
Which drugs raise risk of urinary tract infections?
29 Jul 2022
SOUNDS: Real-world use affirms efficacy, safety of sacral neuromodulator device for OAB
Delivering electric stimulation to the sacral nerves using an implantable device appears to be safe and effective in the treatment of overactive bladder (OAB) in a real-world setting, according to the France-based SOUNDS study presented at the 37th Annual European Association of Urology Congress (EAU 2022).
SOUNDS: Real-world use affirms efficacy, safety of sacral neuromodulator device for OAB
28 Jul 2022
Short-course quinolones, pivmecillinam on par with standard regimens in uncomplicated cystitis
For women with acute uncomplicated cystitis, treatment regimens that include third- and fourth-generation quinolones and pivmecillinam can be administered in shorter courses, which perform similarly to the currently recommended regimens in terms of achieving symptomatic cure, according to the results of a meta-analysis presented at the 37th Annual European Association of Urology (EAU) Congress.